|
AU2004253770C1
(en)
|
2003-07-02 |
2010-04-15 |
Innate Pharma |
PAN-KIR2DL NK-receptor antibodies and their use in diagnostik and therapy
|
|
US20090191213A9
(en)
*
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
|
ES2732623T3
(es)
*
|
2005-01-06 |
2019-11-25 |
Innate Pharma Sa |
Tratamientos y métodos de combinación anti-KIR
|
|
WO2010065939A1
(en)
|
2008-12-05 |
2010-06-10 |
Indiana University Research & Technology Corporation |
Combination therapy to enhace nk cell mediated cytotoxicty
|
|
WO2010117729A1
(en)
|
2009-03-30 |
2010-10-14 |
Portola Pharmaceuticals, Inc. |
Antidotes for factor xa inhibitors and methods of using the same
|
|
EP2453910B1
(en)
*
|
2009-07-15 |
2016-08-31 |
Portola Pharmaceuticals, Inc. |
Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
|
|
EP3514170A1
(en)
*
|
2010-10-22 |
2019-07-24 |
Dana-Farber Cancer Institute, Inc. |
Discovery of regulatory t cells programmed to suppress an immune response
|
|
EA035033B1
(ru)
*
|
2010-11-22 |
2020-04-20 |
Иннейт Фарма Са |
Способ лечения гематологического предракового или гематологического ракового заболеваний
|
|
KR20120093002A
(ko)
*
|
2011-02-14 |
2012-08-22 |
(주)에이티젠 |
Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
|
|
JP6342325B2
(ja)
|
2011-05-25 |
2018-06-13 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
炎症性障害の治療のための抗ｋｉｒ抗体
|
|
EP2904011B1
(en)
*
|
2012-10-02 |
2017-08-23 |
Bristol-Myers Squibb Company |
Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
|
|
CN105025925A
(zh)
*
|
2013-03-15 |
2015-11-04 |
拜尔健康护理有限责任公司 |
抗-催乳素受体抗体制剂
|
|
US10494433B2
(en)
|
2013-11-06 |
2019-12-03 |
Bristol-Myers Squibb Company |
Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
|
|
US11639384B2
(en)
|
2014-10-28 |
2023-05-02 |
University Children's Hospital Tübingen |
Treatment of pediatric BCP-ALL patients with an anti-KIR antibody
|
|
DK3283107T3
(da)
|
2015-04-17 |
2020-08-31 |
Bristol Myers Squibb Co |
Sammensætninger omfattende en kombination af ipilimumab og nivolumab
|
|
EP3907285A1
(en)
|
2015-05-06 |
2021-11-10 |
Snipr Technologies Limited |
Altering microbial populations & modifying microbiota
|
|
SG10202002131PA
(en)
|
2015-05-21 |
2020-05-28 |
Harpoon Therapeutics Inc |
Trispecific binding proteins and methods of use
|
|
CN107921087A
(zh)
|
2015-07-16 |
2018-04-17 |
百欧肯治疗有限公司 |
治疗癌症的组合物及方法
|
|
US20190038713A1
(en)
|
2015-11-07 |
2019-02-07 |
Multivir Inc. |
Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
JP2018536404A
(ja)
|
2015-11-09 |
2018-12-13 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
|
|
JP2019506438A
(ja)
*
|
2016-02-24 |
2019-03-07 |
チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド |
がんの処置のためのｓｍｃ組合せ療法
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
JP7169195B2
(ja)
|
2016-05-20 |
2022-11-10 |
バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド |
癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
JP7542946B2
(ja)
|
2016-09-27 |
2024-09-02 |
ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム |
マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
|
|
MX386249B
(es)
|
2016-10-12 |
2025-03-18 |
Univ Texas |
Terapia tusc2 para usarse en el tratamiento de cáncer.
|
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
|
WO2018183928A1
(en)
|
2017-03-31 |
2018-10-04 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
CN121159691A
(zh)
|
2017-05-12 |
2025-12-19 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
EA202090817A1
(ru)
|
2017-10-13 |
2020-09-08 |
Харпун Терапьютикс, Инк. |
Триспецифические белки и способы их применения
|
|
KR20200064132A
(ko)
|
2017-10-15 |
2020-06-05 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
CN112020510B
(zh)
|
2018-03-19 |
2024-10-11 |
茂体外尔公司 |
包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物
|
|
TW202003565A
(zh)
|
2018-03-23 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
抗mica及/或micb抗體及其用途
|
|
GB2587521B
(en)
|
2018-03-25 |
2023-06-21 |
Snipr Biome Aps |
Treating & preventing microbial infections
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
US20210032344A1
(en)
|
2018-03-30 |
2021-02-04 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
JP2021528393A
(ja)
|
2018-06-15 |
2021-10-21 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
後細胞シグナル伝達因子の調節による免疫活性の上昇
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
AU2019346466A1
(en)
|
2018-09-25 |
2021-05-20 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
US20220054524A1
(en)
|
2018-12-21 |
2022-02-24 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
|
MA55033A
(fr)
|
2019-02-18 |
2021-12-29 |
Lilly Co Eli |
Formulation d'anticorps thérapeutique
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
US20220233691A1
(en)
|
2019-05-30 |
2022-07-28 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
JP2022534967A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
多腫瘍遺伝子シグネチャーおよびその使用
|
|
CN114127315A
(zh)
|
2019-05-30 |
2022-03-01 |
百时美施贵宝公司 |
鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
TW202214857A
(zh)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
新型結合核酸分子及其用途
|
|
CA3184366A1
(en)
|
2020-06-29 |
2022-01-06 |
Darby Rye Schmidt |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
AU2021306613A1
(en)
|
2020-07-07 |
2023-02-02 |
BioNTech SE |
Therapeutic RNA for HPV-positive cancer
|
|
BR112023003553A2
(pt)
|
2020-08-31 |
2023-04-04 |
Bristol Myers Squibb Co |
Assinatura de localização celular e imunoterapia
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
JP2024501029A
(ja)
|
2020-12-28 |
2024-01-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
|
|
EP4566674A3
(en)
|
2020-12-28 |
2025-08-06 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
CA3209479A1
(en)
|
2021-02-03 |
2022-08-11 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
CA3224374A1
(en)
|
2021-06-29 |
2023-01-05 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
JP2024525758A
(ja)
|
2021-07-13 |
2024-07-12 |
ビオンテック・ソシエタス・エウロパエア |
がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
CA3240558A1
(en)
|
2021-12-16 |
2023-06-22 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
JP2025509749A
(ja)
|
2022-03-18 |
2025-04-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
ポリペプチドの単離方法
|
|
US20250332252A1
(en)
|
2022-06-02 |
2025-10-30 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
KR20250120305A
(ko)
|
2022-12-14 |
2025-08-08 |
아스텔라스 파마 유럽 비.브이. |
Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|